Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Get Free Report) traded up 11.9% during mid-day trading on Thursday . The stock traded as high as $2.24 and last traded at $2.17. 43,768 shares were traded during mid-day trading, a decline of 38% from the average session volume of 70,250 shares. The stock had previously closed at $1.94.
Analyst Upgrades and Downgrades
Separately, HC Wainwright upped their target price on Armata Pharmaceuticals from $7.00 to $9.00 and gave the company a "buy" rating in a report on Monday, May 19th.
View Our Latest Stock Analysis on Armata Pharmaceuticals
Armata Pharmaceuticals Stock Down 6.0%
The firm has a market capitalization of $73.83 million, a PE ratio of -2.46 and a beta of 0.94. The stock has a 50 day moving average price of $1.81.
Armata Pharmaceuticals Company Profile
(
Get Free Report)
Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.
Featured Articles
Before you consider Armata Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Armata Pharmaceuticals wasn't on the list.
While Armata Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
